Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial*

FA Post, Y Yazdanpanah, G Schembri, A Lazzarin, Jacques Reynes, Franco Maggiolo, M Yan, ME Abram, C Tran-Muchowski, Andrew Tai Ann Cheng, MS Rhee

Research output: Contribution to journalArticlepeer-review

Abstract

Background: FTC/TAF was shown to be noninferior to FTC/TDF with advantages in markers of renal and bone safety. Objective: To evaluate the efficacy and safety of switching to FTC/TAF from FTC/TDF by third agent (boosted protease inhibitor [PI] vs. unboosted third agent). Methods: We conducted a 48-week subgroup analysis based on third agent from a randomized, double blind study in virologically suppressed adults on a FTC/TDF-containing regimen who switched to FTC/TAF vs. continued FTC/TDF while remaining on the same third agent. Results: We randomized (1:1) 663 participants to either switch to FTC/TAF (N = 333) or continue FTC/TDF (N = 330), each with baseline third agent stratifying by class of third agent in the prior treatment regimen (boosted PI 46%, unboosted third agent 54%). At week 48, significant differences in renal biomarkers and bone mineral density were observed favoring FTC/TAF over FTC/TDF (p 
Original languageEnglish
Pages (from-to)135-140
Number of pages6
JournalHIV Clinical Trials
Volume18
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Dive into the research topics of 'Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup>*</sup>'. Together they form a unique fingerprint.

Cite this